P latelets are an important component of occlusive thrombi that form in arteries diseased by atherosclerosis.1 Platelet activation in atherosclerotic vessels is probably initiated by a number of different processes, including atherosclerotic plaque rupture and shear stress. Plaque rupture exposes thrombogenic subendothelial matrix components that bind von Willebrand factor and cause platelet adherence and aggregation. In addition, thrombin generation initiated by plaque disruption further contributes to platelet aggregation.
Platelet-dependent thrombus formation may also be induced by high shear stress occurring at arterial sites where underlying atheroma or hemorrhage have caused severe arterial narrowing. Phillips, Moake, and colleagues2-4 recently demonstrated that shear stress-induced platelet aggregation is dependent on large von Willebrand factor multimers and the platelet surface receptors, glycoproteins lb and IIb/lIla. In addition, they postulated that localized endothelial cell dysfunction can result in release of unusually large von Willebrand factor multimers that accelerate this process. 23 Weiss et a15 have also reported that von Willebrand factor interactions with both glycoproteins lb and JIb/lIla are essential for platelet aggregation to occur under conditions of increased shear stress. The pivotal role for von Willebrand factor in shear stress-induced platelet aggregation is further supported by the observations that neither fibrinogen nor arachidonate metabolism contributes to shear-induced platelet aggregation and that von Willebrand factor binding to glycoprotein lb can result in platelet activation.4-7 Thus, it is possible that shear stress-induced von Willebrand factor-dependent platelet aggregation is a cause of platelet thrombus formation in constricted arteries.
We have previously reported2 that aurintricarboxylic acid, a triphenylmethyl dye compound, inhibits platelet aggregation in a shear field. Our data indicated that aurintricarboxylic acid bound to von Willebrand factor and inhibited von Willebrand factor interaction with glycoprotein lb. Aurintricarboxylic acid had no effect on platelet metabolic processes and did not inhibit platelet aggregation induced by ADP or thrombin. In the present study, we have evaluated the ability of aurintricarboxylic acid to inhibit plateletdependent thrombus formation in an in vivo model of coronary thrombosis. In this model system, described by Folts and colleagues,8'9 cyclic reductions in coronary blood flow occur due to platelet-dependent thrombi forming at the site of a coronary stenosis created by the placement of a fixed constrictor.
Methods

Materials
Conditioned dogs of both sexes weighing [20] [21] [22] [23] [24] [25] kg were used in this study. The trisodium salt of aurintricarboxylic acid ( Figure 1) 
Surgical Preparation
In this study, we used the canine acute coronary occlusion model developed by Folts and colleagues.8 '9 Mongrel dogs were anesthetized with sodium pentobarbital (30 mg/kg i.v.), intubated with a cuffed endotracheal tube, and ventilated on room air by a respirator (Harvard, Apparatus, South Natick, Massachusetts). Body temperature was maintained at 37-390 C with radiant heat and a heating pad. An 8F arterial sheath and venous catheter were inserted into the right femoral artery and vein, respectively, for continuous monitoring of blood pressure, administration of fluids, and subsequent angiography. All fluids infused were warmed to body temperature. A left thoracotomy was performed at the fifth intercostal space, and the heart was exposed. A small pericardial window was created at the level of the midleft circumflex coronary artery, and a 2-cm segment of the left circumflex artery was exposed and dissected free from the surrounding tissue. All branches of the circumflex artery within the dissected segment were ligated. A pulsed-wave Doppler flow probe (Biomedical Engineering, University of Iowa, Iowa City) was placed around the proximal portion of the dissected vessel, followed by a calibrated electromagnetic flow probe (model 501B, Carolina Medical Equipment). A small polyethylene catheter was then placed into the left atrium and connected to a pressure transducer (Gould, Cleveland, Ohio) for monitoring of left atrial pressures and for later administration of the thromboxane A2 mimetic, U46619.
After the animal was allowed to stabilize for approximately 15 minutes, baseline coronary blood flow, blood pressure, heart rate, and left atrial pressures were recorded and displayed on an eightchannel recorder (model 2800, Gould). To provide control values for subsequent comparison, the coronary artery was occluded for 20 seconds with suture and then released with recording of the hyperemic response. After coronary blood flow returned to normal, a cylindrical plastic (Lexan) constrictor modeled after those described by Folts and colleagues8,9 was placed on the isolated segment of the circumflex artery 1 cm distal to the Doppler and electromagnetic flow probes. In each animal, we used a constrictor that attenuated or abolished the hyperemic response after coronary occlusion but that did not cause an immediate reduction in blood flow. Cyclic flow reductions (CFRs) due to platelet-dependent thrombus formation occurred shortly after placement of the constrictor. These gradual declines in coronary blood flow velocity were occasionally interrupted by spontaneous restorations in flow through the stenotic artery. In most instances, blood flow through the constricted coronary artery was restored by manually moving the constrictor around the artery after the flow signal declined to near zero. Once CFRs developed, the animals were continuously monitored for 30 minutes so that baseline CFR frequency, phasic and mean coronary blood flow, blood flow velocity, heart rate, and left atrial and systemic blood pressure responses could be documented. The in vitro and ex vivo effect of aurintricarboxylic acid on platelet aggregation was evaluated. In vitro studies were conducted on dog platelet-rich plasma prepared from blood drawn by a double-syringe technique into trisodium citrate anticoagulant (final anticoagulant concentration, 0.38%). The dogs used for this purpose had been trained to undergo venipuncture and phlebotomy. Aurintricarboxylic acid dissolved in phosphate buffer was added to plateletrich plasma to achieve final concentrations ranging from 0 to 600 ,umol/l. Buffer alone was added to control samples. Platelet aggregation after addition of both 12.5 ,umol/l ADP and 0.25 Atmol/l epinephrine was measured turbidimetrically with an aggregometer (Sienco, Morrison, Colorado).
Ex vivo analysis of ADP/epinephrine-induced platelet aggregation was performed on platelet-rich plasma obtained from study and control animals before and after administration of aurintricarboxylic acid or buffer. The platelet aggregation response after drug infusion was compared with pretreatment response. Thrombin time determinations on plasma were performed by the method of Clauss13 in a fibrometer (BBL Microbiology Systems, Cockeysville, Maryland).
Effect ofAurintricarboxylic Acid on Shear-Induced Platelet Aggregation In Vitro
Shear-induced platelet aggregation was studied as previously described by using the Ferranti cone and plate viscometer (Ferranti Electric, Commack, New York).2,3 Samples of canine platelet-rich plasma were applied to the plate in the presence or absence of aurintricarboxylic acid or buffer. Before and after shearing, samples were taken for particle counting. A shear force of 180 dynes/cm2 was applied for 30 seconds. Particle counts were performed in an electronic particle counter and channelyzer (model ZBI, Coulter Diagnostics, Hialeah, Florida). The sample volume for counting was 100 ,ul, and the aperture setting was 50 ,um. Particles with sizes +20% of the mean platelet distribution in the unsheared samples were considered as single platelets. The disappearance of single platelets could be accounted for by the formation of platelet aggregates. Thus, the percent decrease in single platelets was directly related to the percent increase in platelet aggregates. All counts were done in duplicate.
Statistical Analysis
All values are expressed as mean+SEM. The data were analyzed by ANOVA for repeated measures. The calculated p values were adjusted to account for multiple data points derived from each animal. Paired Student's t test was used to determine whether a significant change in a variable occurred within the animals studied. A value ofp<0.05 was used to define a significant difference between values.
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Results
Baseline Hemodynamics and Constriction-Induced Changes in Coronary Artery Blood Flow
Of the 16 dogs studied, 15 dogs exhibited CFRs after placement of the coronary artery constrictor. Coronary blood flow in the constricted circumflex artery was minimally reduced; however, maximal hyperemic response after a 20-second occlusion declined from 332+38% of basal flow in nonoccluded vessels to 143+14% of basal flow in constricted vessels. These parameters were comparable in all experimental and control groups. Heart rate and blood pressure remained unchanged for the duration of the study.
Effect ofAurintricarboxylic Acid on Cyclic Flow Reductions
After CFRs were monitored for 30 minutes, aurintricarboxylic acid was administered to each of six animals in incremental doses of 1 mg/kg every 10 minutes after an initial 4 mg/kg bolus dose. Before drug infusion, CFR frequency was 20±2 cycles/hr, and the mean decrease in blood flow was 10±3 cm3/min. In each animal, aurintricarboxylic acid abolished CFRs in a dose-related fashion. Figure 2 illustrates the typical response to aurintricarboxylic acid infusion during the occurrence of CFRs. Figure  3 summarizes the data from all six animals and illustrates the dose-response relation between the cumulative amount of aurintricarboxylic acid infused and its effect on both the frequency of CFRs and their course (decrease in blood flow over time). The average dose of aurintricarboxylic acid needed for total inhibition of CFRs was 6.7±0.4 mg/kg.
In three animals, after complete inhibition of CFRs was achieved, 6 ,ug of the thromboxane A2 mimetic U46619 was applied directly to the vessel at the site of constriction and also injected as a bolus dose through the left atrial catheter. Although a modest increase in heart rate and blood pressure was observed, CFRs did not return. In three other animals, also after inhibition of CFRs, epinephrine was administered as a continuous infusion at a rate of 0. 4 ,ug/kg/min. Epinephrine caused an increase in blood pressure, heart rate, and coronary blood flow lasting approximately 10 minutes. In all three animals, CFRs returned within 6 minutes of initiating the epinephrine infusion. While the infusion was continued, additional bolus doses of aurintricarboxylic acid were administered every 10 minutes. After infusion of an additional 3.7±0.7 mg/kg, total inhibition of CFRs was again achieved (Figure 2 ).
From the studies described above, we determined that a total dose of 10±0.6 mg/kg aurintricarboxylic acid should induce total inhibition of cyclic flow reductions, even in the presence of epinephrine. To evaluate this, four animals were given 10 mg/kg single-bolus infusions. We observed total inhibition of CFRs lasting 173+±8 minutes; the onset of effect was seen within 1-3 minutes of drug administration. There were no hemodynamic changes associated with the effect of aurintricarboxylic acid. Mean heart rate and blood pressure remained stable throughout the course of each experiment (Table 1) . Similarly, in another animal, a single 10 mg/kg bolus infusion of aurintricarboxylic acid inhibited CFRs occurring during constant infusion of epinephrine (0.4 ,gtg/kg/min).
Four animals served as controls. After initiation of CFRs and continuous monitoring for 30 minutes, each animal was given a bolus infusion of the phosphate buffer used as the drug vehicle. Over a 3-hour period after buffer infusion, the frequency of CFRs did not change significantly (Table 1) .
Calculated Shear Stress in Constricted Vessels
Quantitative coronary angiographic analysis of the stenosed coronary artery was performed in all animals receiving aurintricarboxylic acid. The percent vessel stenosis averaged 83%, with a minimal crosssectional area of 0.94 mm2. Mean calculated shear stress at peak diastolic flow was 403 + 114 dynes/cm2 in animals that received incremental doses of aurintricarboxylic acid and 299±117 dynes/cm2 in animals that received a bolus of aurintricarboxylic acid (the difference in shear stress between these groups was not significant, p>0.5) ( Table 2) .
Analysis of the dose-response experiments did not indicate any correlation between the degree of shear stress at the site of constriction and total amount of aurintricarboxylic acid needed to inhibit CFRs. Moreover, there was no correlation noted between the inhibitory dose of aurintricarboxylic acid and the percent vessel lumen stenosis, minimal crosssectional area of the stenosed vessel, or peak coronary blood flow. CFRs returned during intravenous epinephrine challenge in all animals studied. However, there was no appreciable augmentation of shear stress during the epinephrine infusion period. Effect ofAurintricarboxylic Acid on Platelet and Clotting Parameters Platelet aggregation studies were performed on canine platelet-rich plasma to which aurintricarboxylic acid was added in vitro and on platelet-rich plasma prepared from animals that were receiving aurintricarboxylic acid. No inhibition of ADP/ epinephrine-induced platelet aggregation was observed when 100-600 ,gmol/l aurintricarboxylic acid was added to normal platelet-rich plasma ex vivo. Similarly, thrombin time determinations were unaffected by the addition of 10-400 ,umol/l aurintricarboxylic acid to canine normal plasma.
Serial blood samples were obtained from 14 dogs constituting all three groups (dose-response, single dose, and control). Thrombin time, platelet count, and ADP/epinephrine-induced platelet aggregation studies were performed ( shear. When a shear stress of 180 dynes/cm2 was applied for 30 seconds to canine platelet-rich plasma, the platelet count declined 55+±28% (mean±+SD) of preshear control values. The addition of aurintricarboxylic acid to platelet-rich plasma inhibited shear stressinduced aggregation. At a concentration of 350 ,umol/l, aurintricarboxylic acid totally inhibited shear stressinduced aggregation (final platelet count 108+20% of preshear platelet count). This is in marked contrast to the lack of inhibition by aurintricarboxylic acid of ADP/ epinephrine-induced aggregation in the aggregometer.
We also examined the effect of aurintricarboxylic acid on shear stress-induced aggregation of washed canine platelets suspended in buffer containing very large human von Willebrand factor multimers. These von Willebrand factor species are obtained by adding supernatant from cultured human umbil- bolic inhibition of platelet activation, by blockade of the glycoprotein Ilb/Illa receptor, or by infusion of antibody that binds to von Willebrand factor and inhibits von Willebrand factor-glycoprotein lb binding. Thus, data indicate that both platelet activation and the platelet surface glycoproteins lb and lIb/Illa are necessary for thrombus formation within constricted coronary arteries. However, these studies did not identify the specific process that initiated platelet activation.
We suspect that shear stress may be an important cause of platelet activation and aggregation in constricted coronary arteries. Other investigators2-4 have already suggested this, and recent data from in vitro test systems confirmed that shear stress can induce platelet aggregation. In this study, we found that shear stress was elevated at the site of coronary constriction and that the average value obtained (350 dynes/cm2) was greater than the shear stress needed to aggregate canine platelets in vitro (180 dynes/cm2).
Phillips et a12 demonstrated that large von Willebrand factor multimers were necessary for shear stress-induced platelet aggregation. Platelet activation in a shear stress field occurred in the absence of thrombin generation and did not require platelet secretion or exogenous fibrinogen. It is possible that shear stress initiates von Willebrand factor binding to glycoprotein Ib, which results in platelet activation. This mechanism would be consistent with the observation that platelet activation occurred after spontaneous binding of asialo-von Willebrand factor to glycoprotein Ib.6,7
Recently Phillips et a12 reported that aurintricarboxylic acid inhibited shear stress-induced platelet aggregation in vitro. Their data indicated that this effect was mediated by means of aurintricarboxylic acid binding to von Willebrand factor, which prevented its interaction with glycoprotein lb. Based on these data and those discussed above, it seemed appropriate to test the effect of aurintricarboxylic acid on platelet thrombus formation in vivo. Our data clearly indicated that aurintricarboxylic acid was an effective inhibitor of platelet thrombus formation at sites of arterial constriction and elevated shear stress.
Shear stress was elevated at the site of constriction in all animals studied; however, there did not appear to be a direct correlation between the magnitude of shear stress achieved and the total dose of aurintricarboxylic acid needed to inhibit CFRs. It is possible that the dosage needed correlated more closely with plasma von Willebrand factor levels. This would be consistent with the previous in vitro finding2 that the degree of inhibition of shear stress-induced platelet aggregation by aurintricarboxylic acid was directly dependent on its concentration and that of von Willebrand factor in the reaction mixture.
To validate our in vivo observations, we examined the effect of aurintricarboxylic acid in vitro in canine platelet-rich plasma. As observed with human platelets, shear stress caused rapid aggregation of canine platelets. This response was totally inhibited by addi-tion of aurintricarboxylic acid to the platelet-rich plasma. In contrast, aurintricarboxylic acid added in vitro to canine platelet-rich plasma had no inhibitory effect on ADP/epinephrine-induced platelet aggregation. Similarly, the aggregation response of platelets obtained from animals receiving enough aurintricarboxylic acid to totally inhibit CFRs appeared normal.
It remains possible that the mechanism by which aurintricarboxylic acid inhibited platelet thrombus formation in vivo was more complex than that implied by in vitro studies. 2 We observed that epinephrine infusion caused CFRs to return after initial inhibition by aurintricarboxylic acid. It is not known how epinephrine infusion reinitiates CFRs; however, we did not detect a significant increase in shear stress associated with its infusion. Thus, further studies seem warranted to further characterize the platelet inhibitory action of aurintricarboxylic acid in vivo. Coagulation studies did not identify an adverse effect of aurintricarboxylic acid. Platelet counts did not decline significantly in the control or experimental treatment groups. Fibrinogen concentration and coagulability were also unaffected by aurintricarboxylic acid. Thus, abolition of CFRs did not result from platelet destruction or inhibition of fluid phase coagulation. No other acute toxic effects of aurintricarboxylic acid were detected. In particular, we did not observe any effect on blood pressure or heart rate.
Currently, little data is available about possible acute or chronic adverse effects of aurintricarboxylic acid; therefore, its potential use as a pharmaceutical agent is entirely unknown.
Direct inhibition of platelet interaction with adhesive glycoproteins appears to be an effective means of preventing acute arterial occlusion in experimental models of coronary stenosis. Recent studies by our laboratory19 and others20 have demonstrated that blockade of the Agr-Gly-Asp sequence-receptor region of the glycoprotein Ilb/lIla complex inhibits CFRs in stenosed canine coronary arteries. The effect of aurintricarboxylic acid is unique: it inhibits glycoprotein lb-mediated platelet adhesion and subsequent aggregation. This effect is von Willebrand factor dependent, fibrinogen independent, and effective in high shear fields. [2] [3] [4] [5] The results of this study using the model of coronary thrombus formation described by Folts and colleagues8,9 indicated that aurintricarboxylic acid was a potent inhibitor of platelet-dependent thrombus formation. Our observations suggest that inhibition of glycoprotein lb-von Willebrand factor interaction may prove to be an effective means of preventing acute arterial thrombosis. How closely these studies relate to events that occur in human disease cannot be said with certainty; however, aurintricarboxylic acid holds promise as a prototype for a new class of arterial antithrombotic agents.
